This review summarises impor tant pharmacological properties and clinical efficacy and tolerability characteristics of ixekizumab (Taltz®) in the treatment of moderate-to-severe plaque psoriasis in the context of novel approaches to therapy and against the background of the considerable disease burden of psoriasis.
Independent commentary provided by Clinical Associate Professor Kurt Gebauer who has
been practicing dermatology for 20 years in Australia. A/Prof Gebauer is a well-known authority on dermatological conditions. Along with his dermatology practice A/Prof Gebauer also participates in
clinical research studies in order to offer new and innovative treatments for dermatological
conditions including acne, atopic dermatitis, psoriasis, actinic keratoses, onychomycosis, and skin cancer.
Please login below to download this issue (PDF)